

FINAL REPORT

Doe, Jane

Date of Birth: 09/20/1980 (40 yrs)
 Gender: Female
 Patient Id: 123-AB-12
 Patient Location: COVID Test Client

Ordering Provider

Ron McGlennen MD
 7400 Flying Cloud Drive
 Minneapolis, MN 55344
 855-672-5362


Sample Information

Specimen#: 5115335222
 Accession#: 202103-16570
 Specimen: Oral Rinse
 Collected: 03/10/2021
 Received: 03/10/2021 16:03
 Reported: 03/11/2021 12:12

Reason for Testing: Asymptomatic
Related info: Not Provided

MOLECULAR DETECTION OF SARS-COV-2

Test Results	
SARS-CoV-2	Not Detected



Signs and Symptoms

- Fatigue
- Sore throat
- Dry cough
- Shortness of breath
- Fever
- Nausea
- Diarrhea

Interpretation:

The submitted sample is negative (absence of the RNA) for SARS-CoV-2, the virus that causes the disease called COVID-19. See comments.


Guidance from the Centers for Disease Control and Prevention:

- **General information about SARS-CoV-2:**
 - <https://www.cdc.gov/coronavirus/2019-ncov/index.html>
- **Information on testing for SARS-CoV-2:**
 - <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html>
 - <https://www.cdc.gov/coronavirus/2019-ncov/testing/diagnostic-testing.html>
- **Guidance for Healthcare Providers:**
 - <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html>
 - <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care.html>
 - <https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html>

Fact Sheets:

- **Healthcare Provider:**
 - <https://www.fda.gov/media/140291/download>
- **Patient:**
 - <https://www.fda.gov/media/140292/download>

Methodology: Based on 1 mL of primary sample, 300 uL is used to extract viral RNA and cellular DNA using the Chemagic Viral 300 360 HP 96 (ABI Perkin Elmer). Following this, reverse transcription is used to create cDNA of the SARS-CoV-2 viral sequence followed by polymerase chain reaction-based amplification of regions of the SAR-Cov-2 genome (ORF1a, RdRp, E and N genes). This rt-PCR test uses the components of the Logix Smart 2019 Novel Coronavirus kit (Co-Diagnostics, Salt Lake City, UT). The results of this test are based on the detection of amplified viral gene sequences along with an internal control gene marker. The results are reported as Detected, Not Detected or Inconclusive. The performance characteristics of this assay was determined by Access Genetics, LLC, d.b.a. OralDNA Labs and is assigned as a laboratory developed test. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by Access Genetics, LLC, d.b.a. OralDNA Labs and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act 21, U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.



Ronald McGlennen MD, FCAP, FACMG, ABMG
Medical Director